Abstract
Compensating mitochondrial complex I function with yeast NDI1 is effective for gene therapy in Aβ-induced AD cell and mouse models. The results of this study offer a novel strategy and approach for treating AD types characterized by complex I abnormalities.
Introduction
Alzheimer’s disease (AD) is traditionally characterized by the accumulation of amyloid-beta (Aβ) plaques and Tau tangles. However, the "mitochondrial cascade" hypothesis suggests that mitochondrial dysfunction—specifically in Complex I, the largest enzyme in the respiratory chain—is a primary driver of the disease. When Complex I fails, neurons face an energy crisis, increased oxidative stress, and eventual cell death.
Repairing mammalian Complex I is genetically challenging due to its 45-subunit structure. This study explores a "molecular bypass" strategy using the yeast protein NDI1. Unlike its mammalian counterpart, NDI1 is a single-subunit enzyme that performs the same essential task of oxidizing NADH. The researchers investigated whether this simpler yeast enzyme could functionally replace the defective mammalian complex in AD environments.
Methods and Materials
The study utilized a combination of in vitro and in vivo models to evaluate the therapeutic potential of NDI1.
- Cellular Model: Human SH-SY5Y neural cells were treated with Aβ1–42 to simulate AD-like pathology. SH-SY5Y neural cells used to model Alzheimer's pathology in vitro. Source, p. 5
- Animal Model: Male C57BL/6 mice received hippocampal injections of Aβ1–42 to induce cognitive and pathological symptoms.
- Gene Delivery: The HA-tagged yeast NDI1 gene was delivered directly into cells and the mouse hippocampus using an Adeno-associated virus serotype 9 (AAV9) vector.
- Analytical Techniques: Mitochondrial function was measured via oxygen consumption rates and ATP bioluminescence. Cognitive health was assessed using the Morris Water Maze (MWM) and Novel Object Recognition (NOR) tests. Pathological markers, including Tau phosphorylation and neuroinflammation (GFAP/Iba-1), were tracked via Western blotting and immunohistochemistry.
Key Insights and Results
The results demonstrate that the "molecular bypass" effectively restores cellular health and cognitive function.
- Complex I and ATP Restoration: In AD model mice, Complex I activity dropped by approximately 67%. NDI1 therapy restored this activity to near-normal levels, significantly increasing ATP production and decreasing damaging Reactive Oxygen Species (ROS).
- Cognitive Recovery: In the Morris Water Maze, AD model mice initially struggled to find the hidden platform. However, NDI1-treated mice showed dramatic improvement, matching the performance of healthy controls by the fifth day of training.
- Mitochondria-Tau Connection: A significant finding was that restoring mitochondrial function reduced the phosphorylation of Tau protein. This suggests that metabolic failure may be a prerequisite for the protein aggregation seen in AD.
- Autophagy Rescue: Aβ typically cripples the cell's ability to clear toxic debris. NDI1 therapy restored lysosomal function (marked by increased LAMP1), allowing for more effective autophagy.
- Safety: Injecting AAV9-NDI1 into healthy mice caused no adverse effects on memory, cell morphology, or inflammation, indicating the therapy is well-tolerated.
Discussion and Future Directions
This study provides a proof-of-concept for using yeast NDI1 as a gene therapy for AD. By bypassing the complex machinery of mammalian mitochondria, the researchers successfully reversed cognitive deficits and reduced pathological markers in acute models.
However, limitations remain. The study used an acute Aβ-injection model; future work must test NDI1 in transgenic AD mouse models that better mimic the slow, chronic progression of the human disease. Additionally, while AAV9 is a clinically approved vector, the potential immunogenicity of a foreign yeast protein in the human brain requires long-term study, although its localization within the mitochondria may help it evade immune surveillance.
Summary updated